Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 6/20 | 0.38 |
| ▸ | UBE2M | P61081 | 6/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 6/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CCR4 | P51679 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL650021 | 0.93 | C5AR1 (0.41) | C5AR1TRPV4CCR4CRHR1 | |
| SCHEMBL5134723 | 0.91 | C5AR1 (0.42) | C5AR1CCR4CRHR1 | |
| SCHEMBL650989 | 0.90 | C5AR1 (0.39) | C5AR1TRPV4UBE2MDCUN1D1ADORA1 | |
| SCHEMBL5137864 | 0.90 | C5AR1 (0.44) | C5AR1ADORA1 | |
| SCHEMBL5135374 | 0.89 | C5AR1 (0.40) | C5AR1CCR4CRHR1MEN1KMT2A | |
| SCHEMBL650105 | 0.88 | C5AR1 (0.46) | C5AR1TRPV4UBE2MDCUN1D1ADORA1 | |
| SCHEMBL649769 | 0.88 | C5AR1 (0.40) | C5AR1TRPV4UBE2MDCUN1D1ADORA1 | |
| SCHEMBL651073 | 0.87 | CCR4 (0.42) | C5AR1TRPV4UBE2MDCUN1D1ADORA1 | |
| SCHEMBL647762 | 0.87 | C5AR1 (0.39) | C5AR1TRPV4ADORA1CCR4CRHR1 | |
| SCHEMBL646859 | 0.87 | C5AR1 (0.39) | C5AR1TRPV4UBE2MDCUN1D1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |